Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients

Methods in Molecular Biology

Volumn 1139, Issue , 2014, Pages 201-221

  Camisaschi, Chiara ^a   Tazzari, Marcella ^a   Rivoltini, Licia ^a   Castelli, Chiara ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CFSE; Immunomagnetic isolation; Intracellular staining; Multiparametric FACS analysis; Regulatory T cells; Suppression assay; Treg depletion

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA;

ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CELL SUSPENSION; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MALIGNANT NEOPLASTIC DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC PLASTICITY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; BIOSYNTHESIS; CELL SEPARATION; CENTRIFUGATION; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; INTRACELLULAR SPACE; METABOLISM; METHODOLOGY; NEOPLASM; STAINING;

CELL SEPARATION; CENTRIFUGATION; CYTOKINES; CYTOLOGICAL TECHNIQUES; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTRACELLULAR SPACE; NEOPLASMS; STAINING AND LABELING; T-LYMPHOCYTES, REGULATORY;

EID: 84909633833     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0345-0_18     Document Type: Article

References (19)

1. Ghiringhelli F et al (2004) CD4 + CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344
2. Lutsiak M et al (2005) Inhibition of CD4 + 25 + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868
3. Ghiringhelli F et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648
4. Slingluff CL et al (2011) Randomized multicenter trial of the effects of melanomaassociated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 29:2924-2932
5. Ge Y et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61:353-362
6. Jacobs JF et al (2010) Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A phase I/II study in metastatic melanoma patients. Clin Cancer Res 16:5067-5078
7. Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99-106
8. Mahnke K et al (2007) Depletion of CD4 + CD25 + human regulatory T cells in vivo: kinetics of treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723-2733
9. Attia P et al (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (denileukin diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28:582-592
10. Morse MA et al (2008) Depletion of human regulatory T cells specifi cally enhances antigenspecific immune responses to cancer vaccines. Blood 112:610-618
11. Dannull J et al (2005) Enhancement of vaccine- mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115:3623-3633
12. Powell DJ et al (2007) Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179:4919-4928
13. Powell DJ et al (2008) Partial reduction of human FOXP3 + CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother 31:189-198
14. Menard C et al (2008) Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 14:5242-5249
15. Ralph C et al (2010) Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 16:1662-1672
16. Finke JH et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674-6682
17. Adotevi O et al (2010) A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33:991-998
18. Desar I et al (2011) Sorafenib reduces the percentage of tumour infi ltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 129:507-512
19. Balachandran VP et al (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of ido. Nat Med 17:1094-1100